After a more than 10 years of research and development, Israel is now here to bring all that they have acquired and mastered to the U.S. marijuana market.
This past month, Tikun Olam, the world’s first, largest and leading supplier of medical marijuana in Israel, announced its expansion to the U.S.— starting with Nevada, just as the state embarks on its journey with adult cannabis use.
To easily prepare itself for the economic growth making its way to Nevada (marijuana was legalized statewide in the last election, and the law is expected to go into effect sometime this year), Tikun is bringing all of its research and methods to the States.
Tikun Olam was Israel’s first medical cannabis company, opening back in 2007, and soon thereafter chosen by the Israeli government in 2007 to be the first government-approved cultivator of medical marijuana. They have also received global accolades for Avidekel, the first ever high-CBD strain.
Tikun Olam (which is defined as “healing the world” in Hebrew) is known for curating its own unique strains that are developed with patient feedback. At their marijuana shop in Tel Aviv, nurses assist patients with treatment but also accumulate data.
“It helps us to understand which strains are working for which conditions,” Bernard Sucher, CEO at Tikun, explained. “It helps us see the entire strain and the entire patient holistically. Our strains were purpose-bred for conditions and ailments.”
Sucher wants to bring that same volume of care and research to the U.S., where limits on federal financing for medical marijuana research have stymied many efforts before they could even begin.
“It’s still extraordinarily challenging to create peer-reviewed research studies in the U.S., but we do plan to collect as much information as possible from our consumers and patients so we can understand how our products specifically are helping improve lives,” Sucher said. “We look forward to collecting that data qualitatively… We can invite patients and consumers to track their consumption with us voluntarily, so we look forward to developing digital methods that will enable us to do so.”
In the end, Tikun Olam’s intent is to provide the best relief it can for its patients.